State Street Corp Has $6.09 Billion Holdings in Bristol Myers Squibb Company $BMY

State Street Corp increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 105,757,638 shares of the biopharmaceutical company’s stock after buying an additional 7,192,724 shares during the period. State Street Corp owned 0.05% of Bristol Myers Squibb worth $6,093,755,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Geode Capital Management LLC grew its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank bought a new stake in Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb in the second quarter valued at approximately $1,436,115,000. Finally, Bank of New York Mellon Corp lifted its stake in Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.1%

Shares of BMY stock traded up $0.06 on Tuesday, hitting $62.68. The stock had a trading volume of 2,184,600 shares, compared to its average volume of 11,850,441. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business has a 50 day moving average of $64.27 and a 200 day moving average of $60.13. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The stock has a market cap of $128.04 billion, a price-to-earnings ratio of 13.80, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BMY. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Citigroup reaffirmed a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, HSBC reissued a “hold” rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.72.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is owned by insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.